| Online-Ressource |
Verfasst von: | Madle, Michael [VerfasserIn]  |
| Krämer, Ines [VerfasserIn]  |
| Giesen, Nicola [VerfasserIn]  |
| Schwarzbich, Mark-Alexander [VerfasserIn]  |
| Wuchter, Patrick [VerfasserIn]  |
| Herfarth, Klaus [VerfasserIn]  |
| Egerer, Gerlinde [VerfasserIn]  |
| Ho, Anthony Dick [VerfasserIn]  |
| Witzens-Harig, Mathias [VerfasserIn]  |
Titel: | The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma |
Verf.angabe: | M. Madle, I. Krämer, N. Lehners, M. Schwarzbich, P. Wuchter, K. Herfarth, G. Egerer, A.D. Ho, M. Witzens-Harig |
E-Jahr: | 2015 |
Jahr: | 14 August 2015 |
Umfang: | 5 S. |
Fussnoten: | Gesehen am 04.06.2020 |
Titel Quelle: | Enthalten in: Annals of hematology |
Ort Quelle: | Berlin : Springer, 1955 |
Jahr Quelle: | 2015 |
Band/Heft Quelle: | 94(2015), 11, Seite 1853-1857 |
ISSN Quelle: | 1432-0584 |
Abstract: | For patients with diffuse large B cell lymphoma without the involvement of the CNS, the addition of rituximab to standard chemotherapy has significantly improved survival. In this single-center, retrospective analysis, a total of 81 primary CNS lymphoma (PCNSL) patients treated in our institution between 2000 and 2011 were included. Beside first-line chemotherapy with or without rituximab, we evaluated the impact of age (≤/>60 years), autologous stem cell transplantation (ASCT +/−), and other factors upon overall survival (OS) and progression-free survival (PFS). In patients treated with rituximab (n = 27), 3-year OS was 77.8 % (95 % confidence interval (CI) 62-93 %). In contrast, in patients treated without rituximab (n = 52), 3-year OS was only 39.9 % (CI 27-53 %, Fig. 1). The difference in OS was significant in the univariate (p = 0.002) as well as in the multivariate analysis (p = 0.049, hazard ratio (HR) = 0.248). Patients ≤60 years of age (n = 28) had a 3-year OS of 78.2 % (CI 63-94 %); in patients >60 years (n = 51), 3-year OS was 38.7 % (CI 25-52 %). Patients who received high-dose therapy and ASCT had a 3-year OS of 85.2 % (CI 72-99 %), and 65.1 % were alive up to the time of analysis (range 9-131 months). Without ASCT, median OS was only 16 months (CI 11-21) and 3-year OS was 35.2 % (CI 22-48 %). Age and ASCT were significantly associated with better OS in univariate (p = 0.002 and p < 0.001) as well in multivariate analysis (p = 0.004, HR = 0.023 and p = 0.001, HR = 0.014). Rituximab treatment, ASCT, and age are independent prognostic factors for OS in the first-line treatment of PCNSL. |
DOI: | doi:10.1007/s00277-015-2470-4 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1007/s00277-015-2470-4 |
| DOI: https://doi.org/10.1007/s00277-015-2470-4 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1699821607 |
Verknüpfungen: | → Zeitschrift |
¬The¬ influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma / Madle, Michael [VerfasserIn]; 14 August 2015 (Online-Ressource)